Literature DB >> 15172743

ApoE genotype accounts for the vast majority of AD risk and AD pathology.

Jacob Raber1, Yadong Huang, J Wesson Ashford.   

Abstract

In this review, evidence is provided that apolipoprotein E (apoE) genotype accounts for the majority of Alzheimer's disease (AD) risk and pathology. The three major human isoforms, apoE2, apoE3, and apoE4, are encoded by different alleles (2, 3, 4) and regulate lipid metabolism and redistribution. ApoE isoforms differ in their effects on AD risk and pathology. Clinical and epidemiological data have indicated that the 4 allele may account for 50% of AD in the United States. Further, the rarity of AD among carriers of the 2 allele suggests that allelic variations in the gene encoding this protein may account for over 95% of AD cases. ApoE4 disrupts memory function in rodents. Further studies have indicated that fragments of apoE may contribute to both plaque and tangle formation. Thus, the epidemiologic and basic science evidence suggest that apoE genotype accounts for the vast majority of AD risk and pathology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172743     DOI: 10.1016/j.neurobiolaging.2003.12.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  191 in total

1.  To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.

Authors:  Maria G Grammatikopoulou; Dimitrios G Goulis; Konstantinos Gkiouras; Xenophon Theodoridis; Kalliopi K Gkouskou; Athanasios Evangeliou; Efthimis Dardiotis; Dimitrios P Bogdanos
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

Review 2.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

3.  Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample.

Authors:  Po H Lu; Grace J Lee; Erika P Raven; Kathleen Tingus; Theresa Khoo; Paul M Thompson; George Bartzokis
Journal:  J Clin Exp Neuropsychol       Date:  2011-08-26       Impact factor: 2.475

4.  Repositioning leptin as a therapy for Alzheimer's disease.

Authors:  Jane M Johnston; Steven J Greco; Ashkan Hamzelou; J Wesson Ashford; Nikolaos Tezapsidis
Journal:  Therapy       Date:  2011-09

5.  Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons.

Authors:  Steven J Greco; Ashkan Hamzelou; Jane M Johnston; Mark A Smith; J Wesson Ashford; Nikolaos Tezapsidis
Journal:  Biochem Biophys Res Commun       Date:  2011-09-17       Impact factor: 3.575

6.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

Review 7.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 8.  Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression.

Authors:  James A Mortimer; Amy R Borenstein; Karen M Gosche; David A Snowdon
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

Review 9.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 10.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.